888-969-2592
Kalkine 0
countryflagCA

Lantheus Holdings Inc

Healthcare US LNTH

78.66USD
0.74(0.95%)

Last update at 2025-06-18T15:11:00Z

Day Range

77.0578.61
LowHigh

52 Week Range

50.2094.47
LowHigh

Fundamentals

  • Previous Close 77.92
  • Market Cap5351.63M
  • Volume131312
  • P/E Ratio11.77
  • Dividend Yield-%
  • EBITDA544.54M
  • Revenue TTM1365.62M
  • Revenue Per Share TTM19.93
  • Gross Profit TTM 581.70M
  • Diluted EPS TTM6.56

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 26.72M -75.03800M -11.47900M 28.63M 49.55M
Minority interest - - - - -
Net income 28.07M -71.27900M -13.47300M 31.67M 40.52M
Selling general administrative 133.58M 150.40M 69.27M 61.24M 50.17M
Selling and marketing expenses 100.24M 68.42M 40.90M 41.89M 43.16M
Gross profit 581.70M 187.69M 138.76M 174.81M 174.88M
Reconciled depreciation 47.93M 42.29M 24.69M 13.38M 13.93M
Ebit -13.43700M -76.08800M -4.19800M 32.06M 53.02M
Ebitda 34.49M -83.43800M -2.00000M 45.44M 66.95M
Depreciation and amortization 47.93M -7.35000M 2.20M 13.38M 13.93M
Non operating income net other -2.29100M -6.46100M 2.20M -9.41700M 2.46M
Operating income -13.43700M -76.08800M -4.19800M 32.06M 64.49M
Other operating expenses 898.87M 501.30M 343.61M 295.68M 278.89M
Interest expense 7.18M 7.75M 9.48M 13.62M 17.41M
Tax provision -1.34800M -3.75900M 1.99M -3.04000M 9.03M
Interest income 2.61M 0.04M 0.24M 0.69M 17.96M
Net interest income -4.57200M -7.70700M -9.24100M -12.93100M -17.40500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.34800M -3.75900M 1.99M -3.04000M 9.03M
Total revenue 935.06M 425.21M 339.41M 347.34M 343.37M
Total operating expenses 545.51M 263.78M 142.96M 123.15M 110.40M
Cost of revenue 353.36M 237.51M 200.65M 172.53M 168.49M
Total other income expense net 40.16M 1.05M -7.28100M -3.43400M 2.46M
Discontinued operations - - - - -
Net income from continuing ops 28.07M -71.27900M -13.47300M 31.67M 40.52M
Net income applicable to common shares 28.07M -71.27900M -13.47300M 31.67M 40.52M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1651.15M 1321.26M 863.78M 869.82M 405.92M
Intangible assets 151.99M 315.29M 348.51M 376.01M 7.34M
Earning assets - - - - -
Other current assets 0.25M 13.09M 12.82M 9.62M 7.28M
Total liab 835.26M 874.11M 399.35M 355.62M 291.32M
Total stockholder equity 815.89M 447.15M 464.44M 514.21M 114.60M
Deferred long term liab - - - - -
Other current liab 15.16M 226.78M 5.35M 1.79M 2.10M
Common stock 0.70M 0.69M 0.68M 0.67M 0.39M
Capital stock 0.70M 0.69M 0.68M 0.67M 0.39M
Retained earnings 133.50M -193.15800M -221.22500M -149.94600M -136.47300M
Other liab - 43.26M 145.73M 77.41M 40.47M
Good will 61.19M 61.19M 61.19M 58.63M 15.71M
Other assets - 125.97M 101.52M 130.78M 92.53M
Cash 713.66M 415.65M 98.51M 79.61M 92.92M
Cash and equivalents - - - - -
Total current liabilities 187.35M 247.70M 90.50M 80.50M 66.11M
Current deferred revenue 130.17M - 52.71M 41.73M 35.26M
Net debt -96.71000M 142.41M 76.25M 138.79M 101.15M
Short term debt 0.82M 0.35M 11.64M 20.70M 10.14M
Short long term debt 0.82M 0.35M 11.64M 20.70M 10.00M
Short long term debt total 616.95M 558.07M 174.76M 218.40M 194.07M
Other stockholder equity 682.73M 640.88M 685.47M 665.53M 251.64M
Property plant equipment - 141.20M 116.77M 120.17M 117.43M
Total current assets 1085.82M 677.62M 235.79M 184.22M 172.91M
Long term investments - - - - -
Net tangible assets - 70.67M 54.74M 79.56M 91.55M
Short term investments - - - - -
Net receivables 284.29M 213.40M 89.34M 54.00M 43.53M
Long term debt 561.67M 557.71M 163.12M 197.70M 183.93M
Inventory 64.03M 35.48M 35.13M 35.74M 29.18M
Accounts payable 41.19M 20.56M 20.79M 16.28M 18.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.03700M -1.25900M -0.48500M -2.04800M -0.96000M
Additional paid in capital - - - - -
Common stock total equity - 0.69M 0.68M 0.67M 0.39M
Preferred stock total equity - - - - -
Retained earnings total equity - -193.15800M -221.22500M -149.94600M -136.47300M
Treasury stock - -75.00000M - - -
Accumulated amortization - - - - -
Non currrent assets other 8.31M 34.35M 38.76M 60.63M 21.63M
Deferred long term asset charges - - - - -
Non current assets total 565.33M 643.64M 627.99M 685.60M 233.01M
Capital lease obligations 54.45M 25.44M 16.55M - 0.33M
Long term debt total - 557.71M 163.12M 197.70M 183.93M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -276.54700M 3.68M -10.00000M -22.06100M -19.13200M
Change to liabilities 51.40M 5.42M -5.55700M -3.84600M 2.58M
Total cashflows from investing activities -276.54700M 3.68M -4.91200M -22.06100M -19.13200M
Net borrowings 382.27M -43.34800M -16.71500M -78.17300M -2.86200M
Total cash from financing activities 311.69M -39.33200M -21.86100M -78.88100M -4.66800M
Change to operating activities 60.60M 16.07M -2.22000M 3.67M 1.59M
Net income 28.07M -71.27900M -13.47300M 31.67M 40.52M
Change in cash 316.59M 17.96M -10.22500M -20.48200M 37.11M
Begin period cash flow 100.65M 82.69M 92.92M 113.40M 76.29M
End period cash flow 417.24M 100.65M 82.69M 92.92M 113.40M
Total cash from operating activities 281.78M 53.92M 16.40M 80.38M 61.19M
Issuance of capital stock 1.38M 0.77M 0.68M 0.57M 0.43M
Depreciation 47.93M 42.29M 24.69M 13.38M 13.93M
Other cashflows from investing activities 1.80M 15.82M 17.56M - 1.00M
Dividends paid - - - - -
Change to inventory -7.50800M -3.54900M -8.45900M 1.99M -8.69000M
Change to account receivables -128.46000M -33.10200M -7.46200M 0.16M -3.98500M
Sale purchase of stock -75.00000M 6.06M -3.01700M 1.75M 1.58M
Other cashflows from financing activities 560.70M 3.25M -7.05300M 195.92M -2.23400M
Change to netincome 70.26M 97.39M 28.15M 18.11M 13.31M
Capital expenditures 18.35M 12.14M 12.47M 22.06M 20.13M
Change receivables -128.46000M -33.10200M -7.46200M 0.16M -3.98500M
Cash flows other operating 218.84M 16.74M -1.61100M 17.95M 42.76M
Exchange rate changes - - - - -0.28200M
Cash and cash equivalents changes 316.93M 18.27M -10.37700M -20.55800M 37.11M
Change in working capital -75.06500M -15.15400M -22.36500M 9.05M -13.97200M
Stock based compensation 29.26M 15.93M 14.07M 12.49M 8.72M
Other non cash items 302.53M 78.48M 14.19M 6.59M 5.87M
Free cash flow 263.43M 41.78M 3.92M 58.32M 41.06M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LNTH
Lantheus Holdings Inc		 0.74 0.95% 78.66 11.77 9.25 3.21 5.11 3.14 8.29
ZTS
Zoetis Inc		 -5.02 3.11% 156.65 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.325 1.27% 25.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -3.3 2.47% 130.20 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.07 0.44% 14.96 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings Inc

201 Burlington Road, Bedford, MA, United States, 01730

Key Executives

Name Title Year Born
Ms. Mary Anne Heino CEO, Pres & Director 1960
Mr. Robert J. Marshall Jr., CFA Chief Financial Officer 1967
Mr. Paul M. Blanchfield Chief Operating Officer 1981
Mr. Daniel M. Niedzwiecki Sr. VP, Gen. Counsel & Corp. Sec. 1977
Mr. Etienne Montagut Chief Bus. Officer 1975
Ms. Andrea Sabens Chief Accounting Officer 1979
Ms. Dorothy Barr Sr. VP of Manufacturing & Technical Operations NA
Mr. Mark Richard Kinarney Sr. Director of Investor Relations NA
Ms. Linda S. Lennox VP of Corp. Communications & Chief of Staff 1965
Melissa Downs Director of Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.